Eprotirome
CAS: 355129-15-6
Rif. 3D-FPA12915
1mg | Fuori produzione | ||
5mg | Fuori produzione | ||
10mg | Fuori produzione | ||
25mg | Fuori produzione | ||
50mg | Fuori produzione |
Informazioni sul prodotto
- 3-((3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenyl)amino)-3-oxopropanoic acid
- 3-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)anilino]-3-oxo-propanoic acid
- 3-[[3,5-Dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]amino]-3-oxopropanoic acid
- Kb 2115
- N-[3,5-Dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenyl]malonamic acid
- Propanoic acid, 3-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)phenoxy]phenyl]amino]-3-oxo-
Eprotirome is a thyroid hormone receptor agonist that is used to treat patients with hepatic steatosis and congestive heart failure. Eprotirome has been shown to increase the rate of metabolism, decrease LDL cholesterol, and reduce the risk of atherosclerotic cardiovascular disease. Eprotirome binds to TRs on the cell surface, which increases intracellular cyclic AMP levels by stimulating adenylyl cyclase. This increases the level of active thyroid hormone in the body and leads to a number of effects including increased energy metabolism, decreased LDL cholesterol, reduced cardiac effects, and increased ldl-c lowering.